- Product Detail
DermaChip®
|
Combining extracellular matrix 3D Cell Culture with CometChip® technology for genetic toxicology testing with in vitro skin models. DermaChip® is a new high throughput assay technology that allows scientists, for the first time, to reliably measure the genotoxic risk of a whole range of environmental agents (including cleaning agents, household products and industrial chemicals as well as cosmetics) to our skin. The Problem It has been shown that risk assessment data from the micronucleus assay together with traditional comet analysisof cells isolated from treated 3D skin culture models is a better predictor of skin toxicity compared to the standard Combining extracellular matrix 3D Cell Culture with CometChip® technology for genetic toxicology testing with in vitro skin models. DermaChip® is a new high throughput assay technology that allows scientists, for the first time, to reliably measure the genotoxic risk of a whole range of environmental agents (including cleaning agents, household products and industrial chemicals as well as cosmetics) to our skin. The Problem It has been shown that risk assessment data from the micronucleus assay together with traditional comet analysisof cells isolated from treated 3D skin culture models is a better predictor of skin toxicity compared to the standard battery of in vitro toxicity assays. However, in some in vitro models, unacceptable backgrounds were observed as a function of skin preparation. This may be a result of the stage of differentiation of the skin and associated DNA damage when assays are performed. One would expect higher comet backgrounds in cells migrating toward the stratum corneum. The Solution DermaChip® combines extracellular matrix 3D Culture technology with CometChip® technology to provide a unique platform able to specifically isolate basal keratinocytes for genetic toxicology testing using in vitro skin models. The elimination of cells migrating to the stratum corneum, that potentially harbour damaged DNA from the analysis, reduces the background for some 3D models. |
|
DermaChip® Identifies and Analyzes DNA Damage in Integrin Beta 1 Basal Cells of Skin. Patent pending DermaChip® Technology DermaChip® is a disposable gel attached to a specially treated glass slide, indexed for 96 well locations, containing thousands of 30 micron sized pores designed to capture and array cells. The gel specifically traps basal keratinocytes expressing integrin beta-1 before they differentiate and migrate to the stratum corneum. During their natural migration, cells stop dividing and ultimately lose their nucleus. During the process, DNA damage accumulates resulting in high comet backgrounds. By trapping basal keratinocytes, we can eliminate this background. Prior to comet analysis, the identity of trapped cells is confirmed by Anti-integrin beta-1 immunostaining labelled with quantum dots. Only basal keratinocytes are included in comet data analysis. More Details Request a copy of poster to be presented at the Beatson International Cancer Conference. Download Presentation (Collaborator: Dean Rosenthal, Georgetown University, Supported by NIEHS R41ES026908) |
-
AMSBIO’s mission is to be a profitable premier provider of quality life science research reagents and services helping customers develop innovative methods, processes, products and medicines. This is achieved by offering small and medium size manufacturers, academic groups and revenue generating biotechs a unique partnership for the global market and by providing state of the art and cost effective solutions to end users and partners.
Formed in 1987 by Sandy Allan and Alex Sim the company’s first offices were in Madrid, Spain. Over the following three years further offices were opened in Italy, Switzerland and the UK. During the formative years of existence AMS helped launch the successful sales campaigns of Stratagene and Invitrogen providing them with an important foothold from which to develop their global brand expansion.
| Request Infomation |
| Recently viewed products |